Review
BibTex RIS Cite

Hipoaktif cinsel istek bozukluğunun yönetimi

Year 2020, Volume: 2 Issue: 4, 133 - 139, 28.12.2020

Yeşim Bayoğlu Tekin Kübra Baki Erin

https://doi.org/10.46969/etlikzubeyde.736664

Abstract

Hipoaktif cinsel istek bozukluğu kadınlarda en sık görülen cinsel istek bozukluğudur. Bu derlemede cinsel fonksiyon
bozukluğu olan kadınlarda azalmış cinsel arzuya yönelik olarak tarama yapılması ve hangi durumlarda kişinin tedaviye
ihtiyacı olduğunun belirlenmesi amaçlanmaktadır. Ayrıntılı tıbbi ve seksüel öykü tedavinin yönlendirilmesinde en önemli
basamaktır. Laboratuvar testleri ayırıcı tanıda önem kazanmaktadır. Tedavi basamaklarında öncelikli olarak hastaya eğitim
ve danışmanlık verilmesi ve davranışsal terapi uygulaması ile başlanmalıdır. Etki eden faktörlerin modifikasyonu önemlidir.
Bu basamaklardan sonra yanıt alınamazsa medikal tedavi uygulanmalıdır.

Keywords

Hipoaktif Cinsel İstek Bozukluğu kadında cinsel fonksiyon bozuklukları azalmış cinsel arzu

Supporting Institution

yok

Project Number

-

References

  • Sungur MZ, Gunduz A. A comparison of DSM-IV-TR and DSM-5 definitions for sexual dysfunctions: critiques and challenges. J Sex Med 2014; 11:364–373.
  • Clayton AH, Goldstein I, Kim NN et al. The International Society for the Study of Women's Sexual Health Process of Care for Management of Hypoactive Sexual Desire Disorder in Women. Mayo Clin Proc 2018; 93:467-487.
  • Clayton AH, Valladares Juarez EM. Female Sexual Dysfunction. Med Clin N Am 2019; 103:681–698.
  • Goldstein I, Kim NN, Clayton AH, et al. Hypoactive sexual desire disorder: International Society for the Study of Women’s Sexual Health (ISSWSH) expert consensus panel review. Mayo Clin Proc 2017; 92:114-128.
  • Clayton AH, Goldfischer ER, Goldstein I, Derogatis L, Lewis- D’Agostino DJ, Pyke R. Validation of the Decreased Sexual Desire Screener (DSDS): a brief diagnostic instrument for generalized acquired female hypoactive sexual desire disorder (HSDD). J Sex Med 2009; 6:730-738.
  • Maserejian NN, Shifren J, Parish SJ, Segraves RT, Huang L, Rosen RC. Sexual arousal and lubrication problems in women with clinically diagnosed hypoactive sexual desire disorder: preliminary findings from the Hypoactive Sexual Desire Disorder Registry for Women. J Sex Marital Ther 2012; 38:41-62.
  • Davison SL, Bell R, Donath S, Montalto JG, Davis SR. Androgen levels in adult females: changes with age, menopause, and oophorectomy. J Clin Endocrinol Metab 2005; 90:3847-3853.
  • Laughlin GA, Barrett-Connor E, Kritz-Silverstein D, von Mühlen D. Hysterectomy, oophorectomy, and endogenous sex hormone levels in older women: The Rancho Bernardo Study. J Clin Endocrinol Metab 2000; 85:645-651.
  • Clayton AH. Female sexual dysfunction related to depression and antidepressant medications. Curr Womens Health Rep 2002; 2:182-187.
  • Johannes CB, Clayton AH, Odom DM, et al. Distressing sexual problems in United States women revisited: prevalence after accounting for depression. J Clin Psychiatry. 2009;70(12):1698-1706.
  • Maseroli E, Fanni E, Cipriani S, et al. Cardiometabolic risk and female sexuality: focus on clitoral vascular resistance. J Sex Med 2016; 13:1651-1661.
  • Panjari M, Bell RJ, Davis SR. Sexual function after breast cancer. J Sex Med 2011; 8:294-302.
  • Fobair P, Spiegel D. Concerns about sexuality after breast cancer. Cancer 2009; 15:19-26.
  • Zimmerman Y, Eijkemans MJ, Coelingh Bennink HJ, Blankenstein MA, Fauser BC. The effect of combined oral contraception on testosterone levels in healthy women: a systematic review and meta-analysis. Hum Reprod Update 2014; 20:76-105.
  • Davis SR, Worsley R, Miller KK, Parish SJ, Santoro N. Androgens and female sexual function and dysfunction findings from the Fourth International Consultation of Sexual Medicine. J Sex Med 2016; 13:168-178.
  • Melmed S, Casanueva FF, Hoffman AR, et al. Diagnosis and treatment of hyperprolactinemia: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011; 96:273-288.
  • Kingsberg SA, Woodard T. Female sexual dysfunction: focus on low desire. Obstet Gynecol 2015; 125:477-486.
  • Kling JM, Manson JE, Naughton MJ, et al. Association of sleep disturbance and sexual function in postmenopausal women. Menopause 2017; 24:604-612.
  • Bradford A. Inhibited sexual desire in women. In: Grossman L, Walfish S, eds. Translating Psychological Research Into Practice. New York, NY: Springer; 2014:427-429.
  • Pyke RE, Clayton AH. Psychological treatment trials for hypoactive sexual desire disorder: a sexual medicine critique and perspective. J Sex Med 2015; 12:2451-2458.
  • Silverstein RG, Brown AC, Roth HD, Britton WB. Effects of mindfulness training on body awareness to sexual stimuli: implications for female sexual dysfunction. Psychosom Med 2011; 73:817-825.
  • Nastri CO, Lara LA, Ferriani RA, et al. Hormone therapy for sexual function in perimenopausal and postmenopausal women. Cochrane Database Syst Rev 2013; (6):CD009672.
  • Wierman ME, Arlt W, Basson R, et al. Androgen therapy in women: a reappraisal; an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2014; 99:3489-3510.
  • Shifren JL, Davis SR, Moreau M, et al. Testosterone patch forthe treatment of hypoactive sexual desire disorder in naturally menopausal women: results from the INTIMATE NM1 Study. Menopause 2007; 14:157.
  • Chiara Achilli, Jyotsna Pundir, Parimalam Ramanathan, Luca Sabatini, Haitham Hamoda, Nick Panay. Efficacy and safety of transdermal testosterone in postmenopausal women with hypoactive sexual desire disorder: a systematic review and meta-analysis. Fertil Steril 2017; 107:475-482.e15.
  • Constantine G, Graham S, Portman DJ, et al. Female sexual function improved with ospemifene in postmenopausal women with vulvar and vaginal atrophy: results of a randomized, placebo-controlled trial. Climacteric 2015; 18:226–232.
  • Katz M, DeRogatis LR, Ackerman R, et al; BEGONIA Trial Investigators. Efficacy of flibanserin in women with hypoactive sexual desire disorder: results from the BEGONIA trial. J Sex Med 2013; 10:1807-1815.
  • Thorp J, Simon J, Dattani D, et al; DAISY Trial Investigators. Treatment of hypoactive sexual desire disorder in premenopausal women: efficacy of flibanserin in the DAISY study. J Sex Med 2012; 9:793-804.
  • Derogatis LR, Komer L, Katz M, et al; VIOLET Trial Investigators. Treatment of hypoactive sexual desire disorder in premenopausal women: efficacy of flibanserin in the VIOLET Study. J Sex Med 2012; 9:1074-1085.
  • John Thorp, James Simon, Dan Dattani, Leslie Taylor, Toshio Kimura, Miguel Garcia Jr, Lynna Lesko, Robert Pyke, DAISY trial investigators. Treatment of hypoactive sexual desire disorder in premenopausal women: efficacy of flibanserin in the DAISY study. J Sex Med 2012; 9:793-804.
  • Leonard R Derogatis, Lawrence Komer, Molly Katz, Michèle Moreau, Toshio Kimura, Miguel Garcia Jr, Glen Wunderlich, Robert Pyke, VIOLET Trial Investigators. Treatment of hypoactive sexual desire disorder in premenopausal women: efficacy of flibanserin in the VIOLET Study. J Sex Med 2012; 9:1074-1085.
  • James A Simon, Sheryl A Kingsberg, Brad Shumel, Vladimir Hanes, Miguel Garcia Jr, Michael Sand. Efficacy and safety of flibanserin in postmenopausal women with hypoactive sexual desire disorder: results of the SNOWDROP trial. Menopause 2014; 21:633-640.
  • Segraves RT, Clayton A, Croft H, Wolf A, Warnock J. Bupropion sustained release for the treatment of hypoactive sexual desire disorder in premenopausal women. J Clin Psychopharmacol 2004; 24:339-342.
  • Mayer D, Lynch SE. Bremelanotide: New Drug Approved for Treating Hypoactive Sexual Desire Disorder. Ann Pharmacother 2020; 54:684-690.
  • Clayton AH, Althof SE, Kingsberg S, et al. Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial. Womens Health (Lond) 2016; 12:325-337.
  • Kingsberg SA, Clayton AH, Portman D, et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstet Gynecol 2019; 134:899-908.

Management of hypoactive sexual desire disorder

Year 2020, Volume: 2 Issue: 4, 133 - 139, 28.12.2020

Yeşim Bayoğlu Tekin Kübra Baki Erin

https://doi.org/10.46969/etlikzubeyde.736664

Abstract

Hypoactive sexual desire disorder is the most common female sexual dysfunction. This review aimed to screen for
decreased sexual desire in women with sexual dysfunction and determine which cases need treatment. Detailed medical
and sexual history is the most critical step in guiding the treatment. Laboratory tests gain importance in the differential
diagnosis. Initial treatment should include education, counselling and behavioral therapy. Modification of contributing
factors is essential. If there is no response after these steps, medical treatment should be applied.

Keywords

Hypoactive sexual desire disorder female sexual dysfunction decreased sexual desire

Project Number

-

References

  • Sungur MZ, Gunduz A. A comparison of DSM-IV-TR and DSM-5 definitions for sexual dysfunctions: critiques and challenges. J Sex Med 2014; 11:364–373.
  • Clayton AH, Goldstein I, Kim NN et al. The International Society for the Study of Women's Sexual Health Process of Care for Management of Hypoactive Sexual Desire Disorder in Women. Mayo Clin Proc 2018; 93:467-487.
  • Clayton AH, Valladares Juarez EM. Female Sexual Dysfunction. Med Clin N Am 2019; 103:681–698.
  • Goldstein I, Kim NN, Clayton AH, et al. Hypoactive sexual desire disorder: International Society for the Study of Women’s Sexual Health (ISSWSH) expert consensus panel review. Mayo Clin Proc 2017; 92:114-128.
  • Clayton AH, Goldfischer ER, Goldstein I, Derogatis L, Lewis- D’Agostino DJ, Pyke R. Validation of the Decreased Sexual Desire Screener (DSDS): a brief diagnostic instrument for generalized acquired female hypoactive sexual desire disorder (HSDD). J Sex Med 2009; 6:730-738.
  • Maserejian NN, Shifren J, Parish SJ, Segraves RT, Huang L, Rosen RC. Sexual arousal and lubrication problems in women with clinically diagnosed hypoactive sexual desire disorder: preliminary findings from the Hypoactive Sexual Desire Disorder Registry for Women. J Sex Marital Ther 2012; 38:41-62.
  • Davison SL, Bell R, Donath S, Montalto JG, Davis SR. Androgen levels in adult females: changes with age, menopause, and oophorectomy. J Clin Endocrinol Metab 2005; 90:3847-3853.
  • Laughlin GA, Barrett-Connor E, Kritz-Silverstein D, von Mühlen D. Hysterectomy, oophorectomy, and endogenous sex hormone levels in older women: The Rancho Bernardo Study. J Clin Endocrinol Metab 2000; 85:645-651.
  • Clayton AH. Female sexual dysfunction related to depression and antidepressant medications. Curr Womens Health Rep 2002; 2:182-187.
  • Johannes CB, Clayton AH, Odom DM, et al. Distressing sexual problems in United States women revisited: prevalence after accounting for depression. J Clin Psychiatry. 2009;70(12):1698-1706.
  • Maseroli E, Fanni E, Cipriani S, et al. Cardiometabolic risk and female sexuality: focus on clitoral vascular resistance. J Sex Med 2016; 13:1651-1661.
  • Panjari M, Bell RJ, Davis SR. Sexual function after breast cancer. J Sex Med 2011; 8:294-302.
  • Fobair P, Spiegel D. Concerns about sexuality after breast cancer. Cancer 2009; 15:19-26.
  • Zimmerman Y, Eijkemans MJ, Coelingh Bennink HJ, Blankenstein MA, Fauser BC. The effect of combined oral contraception on testosterone levels in healthy women: a systematic review and meta-analysis. Hum Reprod Update 2014; 20:76-105.
  • Davis SR, Worsley R, Miller KK, Parish SJ, Santoro N. Androgens and female sexual function and dysfunction findings from the Fourth International Consultation of Sexual Medicine. J Sex Med 2016; 13:168-178.
  • Melmed S, Casanueva FF, Hoffman AR, et al. Diagnosis and treatment of hyperprolactinemia: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011; 96:273-288.
  • Kingsberg SA, Woodard T. Female sexual dysfunction: focus on low desire. Obstet Gynecol 2015; 125:477-486.
  • Kling JM, Manson JE, Naughton MJ, et al. Association of sleep disturbance and sexual function in postmenopausal women. Menopause 2017; 24:604-612.
  • Bradford A. Inhibited sexual desire in women. In: Grossman L, Walfish S, eds. Translating Psychological Research Into Practice. New York, NY: Springer; 2014:427-429.
  • Pyke RE, Clayton AH. Psychological treatment trials for hypoactive sexual desire disorder: a sexual medicine critique and perspective. J Sex Med 2015; 12:2451-2458.
  • Silverstein RG, Brown AC, Roth HD, Britton WB. Effects of mindfulness training on body awareness to sexual stimuli: implications for female sexual dysfunction. Psychosom Med 2011; 73:817-825.
  • Nastri CO, Lara LA, Ferriani RA, et al. Hormone therapy for sexual function in perimenopausal and postmenopausal women. Cochrane Database Syst Rev 2013; (6):CD009672.
  • Wierman ME, Arlt W, Basson R, et al. Androgen therapy in women: a reappraisal; an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2014; 99:3489-3510.
  • Shifren JL, Davis SR, Moreau M, et al. Testosterone patch forthe treatment of hypoactive sexual desire disorder in naturally menopausal women: results from the INTIMATE NM1 Study. Menopause 2007; 14:157.
  • Chiara Achilli, Jyotsna Pundir, Parimalam Ramanathan, Luca Sabatini, Haitham Hamoda, Nick Panay. Efficacy and safety of transdermal testosterone in postmenopausal women with hypoactive sexual desire disorder: a systematic review and meta-analysis. Fertil Steril 2017; 107:475-482.e15.
  • Constantine G, Graham S, Portman DJ, et al. Female sexual function improved with ospemifene in postmenopausal women with vulvar and vaginal atrophy: results of a randomized, placebo-controlled trial. Climacteric 2015; 18:226–232.
  • Katz M, DeRogatis LR, Ackerman R, et al; BEGONIA Trial Investigators. Efficacy of flibanserin in women with hypoactive sexual desire disorder: results from the BEGONIA trial. J Sex Med 2013; 10:1807-1815.
  • Thorp J, Simon J, Dattani D, et al; DAISY Trial Investigators. Treatment of hypoactive sexual desire disorder in premenopausal women: efficacy of flibanserin in the DAISY study. J Sex Med 2012; 9:793-804.
  • Derogatis LR, Komer L, Katz M, et al; VIOLET Trial Investigators. Treatment of hypoactive sexual desire disorder in premenopausal women: efficacy of flibanserin in the VIOLET Study. J Sex Med 2012; 9:1074-1085.
  • John Thorp, James Simon, Dan Dattani, Leslie Taylor, Toshio Kimura, Miguel Garcia Jr, Lynna Lesko, Robert Pyke, DAISY trial investigators. Treatment of hypoactive sexual desire disorder in premenopausal women: efficacy of flibanserin in the DAISY study. J Sex Med 2012; 9:793-804.
  • Leonard R Derogatis, Lawrence Komer, Molly Katz, Michèle Moreau, Toshio Kimura, Miguel Garcia Jr, Glen Wunderlich, Robert Pyke, VIOLET Trial Investigators. Treatment of hypoactive sexual desire disorder in premenopausal women: efficacy of flibanserin in the VIOLET Study. J Sex Med 2012; 9:1074-1085.
  • James A Simon, Sheryl A Kingsberg, Brad Shumel, Vladimir Hanes, Miguel Garcia Jr, Michael Sand. Efficacy and safety of flibanserin in postmenopausal women with hypoactive sexual desire disorder: results of the SNOWDROP trial. Menopause 2014; 21:633-640.
  • Segraves RT, Clayton A, Croft H, Wolf A, Warnock J. Bupropion sustained release for the treatment of hypoactive sexual desire disorder in premenopausal women. J Clin Psychopharmacol 2004; 24:339-342.
  • Mayer D, Lynch SE. Bremelanotide: New Drug Approved for Treating Hypoactive Sexual Desire Disorder. Ann Pharmacother 2020; 54:684-690.
  • Clayton AH, Althof SE, Kingsberg S, et al. Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial. Womens Health (Lond) 2016; 12:325-337.
  • Kingsberg SA, Clayton AH, Portman D, et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstet Gynecol 2019; 134:899-908.
There are 36 citations in total.

Details

Primary Language Turkish
Subjects Obstetrics and Gynaecology
Journal Section Review Article
Authors

Yeşim Bayoğlu Tekin 0000-0003-0865-3201

Kübra Baki Erin 0000-0002-6626-1735

Project Number -
Publication Date December 28, 2020
Acceptance Date November 8, 2020
Published in Issue Year 2020 Volume: 2 Issue: 4

Cite

APA Bayoğlu Tekin, Y., & Baki Erin, K. (2020). Hipoaktif cinsel istek bozukluğunun yönetimi. Türk Kadın Sağlığı Ve Neonatoloji Dergisi, 2(4), 133-139. https://doi.org/10.46969/etlikzubeyde.736664
AMA Bayoğlu Tekin Y, Baki Erin K. Hipoaktif cinsel istek bozukluğunun yönetimi. Türk Kadın Sağlığı ve Neonatoloji Dergisi. December 2020;2(4):133-139. doi:10.46969/etlikzubeyde.736664
Chicago Bayoğlu Tekin, Yeşim, and Kübra Baki Erin. “Hipoaktif Cinsel Istek bozukluğunun yönetimi”. Türk Kadın Sağlığı Ve Neonatoloji Dergisi 2, no. 4 (December 2020): 133-39. https://doi.org/10.46969/etlikzubeyde.736664.
EndNote Bayoğlu Tekin Y, Baki Erin K (December 1, 2020) Hipoaktif cinsel istek bozukluğunun yönetimi. Türk Kadın Sağlığı ve Neonatoloji Dergisi 2 4 133–139.
IEEE Y. Bayoğlu Tekin and K. Baki Erin, “Hipoaktif cinsel istek bozukluğunun yönetimi”, Türk Kadın Sağlığı ve Neonatoloji Dergisi, vol. 2, no. 4, pp. 133–139, 2020, doi: 10.46969/etlikzubeyde.736664.
ISNAD Bayoğlu Tekin, Yeşim - Baki Erin, Kübra. “Hipoaktif Cinsel Istek bozukluğunun yönetimi”. Türk Kadın Sağlığı ve Neonatoloji Dergisi 2/4 (December 2020), 133-139. https://doi.org/10.46969/etlikzubeyde.736664.
JAMA Bayoğlu Tekin Y, Baki Erin K. Hipoaktif cinsel istek bozukluğunun yönetimi. Türk Kadın Sağlığı ve Neonatoloji Dergisi. 2020;2:133–139.
MLA Bayoğlu Tekin, Yeşim and Kübra Baki Erin. “Hipoaktif Cinsel Istek bozukluğunun yönetimi”. Türk Kadın Sağlığı Ve Neonatoloji Dergisi, vol. 2, no. 4, 2020, pp. 133-9, doi:10.46969/etlikzubeyde.736664.
Vancouver Bayoğlu Tekin Y, Baki Erin K. Hipoaktif cinsel istek bozukluğunun yönetimi. Türk Kadın Sağlığı ve Neonatoloji Dergisi. 2020;2(4):133-9.
 Download Cover Image